Blockchain Registration Transaction Record

Oncotelic Unveils PDAOAI Platform and HCC Research at Drug Discovery 2026

Oncotelic showcases PDAOAI platform and HCC research at Drug Discovery 2026, highlighting AI-driven biomedical literature analysis for drug development.

This news matters because it showcases how artificial intelligence can be harnessed to navigate the overwhelming volume of biomedical literature—exemplified by the 29 million PubMed abstracts indexed by PDAOAI—to uncover actionable insights for drug development. By demonstrating a four-gene signature associated with survival in hepatocellular carcinoma, Oncotelic illustrates the potential of AI-driven discovery to identify novel biomarkers and therapeutic targets. As the pharmaceutical industry increasingly turns to AI to streamline research and reduce costs, platforms like PDAOAI could become essential tools for scientists and companies aiming to accelerate the translation of data into treatments. Moreover, the integration of BIO REBOOT to support selected projects suggests a growing ecosystem where computational discoveries are linked with funding and development, potentially bringing new therapies to patients faster.